Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Future Leader, Dr Michelle Korah-Sedgwick discusses her innovative work at the intersection of immunology and respiratory care, focusing on uncovering immune deficiencies in chronic lung disease. She shares insights on personalized treatment approaches, the value of clinical vigilance, and how registries are transforming care for patients with complex respiratory conditions.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
On April 24, 2025, Brussels will host the 4th annual Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day, organized by EUFOREA. This year’s theme, "New Ambitions of Care," focuses on enhancing understanding of CRSwNP, improving early diagnosis, and promoting better treatment strategies for those affected by this debilitating condition.
The current treatment landscape for severe asthma faces major challenges despite biologic advances targeting type 2 inflammation. Current biomarkers like BEC and FeNO inadequately predict treatment response. To optimize precision medicine, improved molecular phenotyping and novel non-invasive biomarkers are urgently needed to better identify asthma endotypes and guide therapy.
The 2025 AAAAI and WAO joint congress highlighted advances in chronic rhinosinusitis (CRS) treatment. Notable studies presented positive results for novel biologic therapies, including tezepelumab, depemokimab and mepolizumab for chronic rhinosinusitis with nasal polyps (CRSwNP), and dupilumab for chronic rhinosinusitis without nasal polyps (CRSsNP). These findings highlight significant advancements in symptom management, offering hope for improved patient outcomes and reduced treatment burdens.
Asthma affects nearly 300 million people worldwide.1Â Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2Â Climate change is also predicted ...
We are excited to welcome you to San Francisco for the ATS 2025 International Conference! Leaders, as well as emerging scientists and clinicians, who are at the forefront of medical breakthroughs and clinical innovation in pulmonary, critical care and sleep medicine will gather for networking and inspiring talks.
GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
The International Primary Care Respiratory Group (IPCRG), is proud to host the 8th IPCRG Scientific Meeting in Brașov, Romania, on Friday 11 and Saturday 12 April 2025. This event, in partnership with the RespiRO team and the Transilvania University of Brașov promises to bring together researchers, innovators, and industry leaders to advance respiratory care in primary health settings.
The International Primary Care Respiratory Group (IPCRG) has initiated a global social movement to bring meaningful change in asthma management. The driving idea behind this initiative is a recognition that, while the current approach may feel sufficient to many, it falls short of optimal care. The IPCRG network sees clear evidence of avoidable harm and unnecessary costs in the current asthma management framework, which continue to impact lives and wellbeing.1 To counteract this, IPCRG's "Asthma Right Care" aims to inspire a shift towards better care practices by reducing both overuse and underuse of effective treatments. This means moving beyond episodic symptom relief and acute responses to establish a chronic care model that adheres to international or national asthma guidelines, prioritizing the appropriate use of anti-inflammatory inhaled medications.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.